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health care costs per controlled patient. Sensitivity analysis
showed that the base study case was robust.
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OBJECTIVE: To compare the economic impact of treating 
neuropathic pain with pregabalin versus gabapentin in Italy.
METHODS: A cost-effectiveness analysis comparing costs and
effects of pregabalin 375 mg/die versus gabapentin 1800 mg/die
in the perspective of the Italian National Health care Service was
developed. The cost effectiveness is examined alternatively in
terms of the incremental cost per additional day with no or mild
pain, and the incremental cost per quality-adjusted life-year
(QALY) gained. Effects were derived from pregabalin random-
ized clinical study 1008-155 and gabapentin 645-210 and 945-
211 studies. Effects are expressed as score reductions on the VAS
pain scale. Pharmacological costs were quantiﬁed according to
the Italian market price of the drugs; health care procedure and
hospitalization costs were quantiﬁed on the basis of the National
Tariff. Other health care services consumption data were derived
from a Delphi Panel. To estimate daily pain experience in
patients with neuropathic pain, and the impact of pregabalin and
gabapentin on it, a stochastic model is used. The dynamic sim-
ulation focuses on a hypothetical cohort of 1000 patients and
simulates their daily pain experience over 12 weeks, to estimate
clinical and economic outcomes for the group as a whole.
RESULTS: The cost-effectiveness ratio for the use of pregabalin
is less than 1 euro per additional day with no or mild pain and
€468 per QALY gained. The sensitivity analysis conducted to
examine the effects of decreasing gabapentin dose to 1200 mg/die
shows consistency of the model results. CONCLUSIONS:
Although pregabalin pharmaceutical costs are higher than
gabapentin costs, the analyses prove pregabalin to be more effec-
tive with a small additional cost per day with no or mild pain.
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OBJECTIVE: Levodopa is the “gold standard” for the sympto-
matic treatment of Parkinson’s Disease (PD) but its beneﬁts
decrease as the disease progresses and motor complications
appear over time. To delay these complications and the need for
levodopa, dopamine agonists (DAs) have been employed as
monotherapy. Our aim was to perform a cost-effectiveness analy-
sis of initiating treatment with rasagiline versus ropinirole in
delaying therapy with levodopa in early PD. METHODS: A 5-
year probabilistic Markov model simulating treatment pathways
of early parkinsonian patients was used to estimate the incre-
mental cost-effectiveness ratio of starting treatment with rasagi-
line or ropinirole. Transition probabilities were derived from
randomized clinical trials and the effectiveness measure was the
number of years until levodopa was required. Since the greatest
portion of direct medical costs of early PD can be attributed to
medication, the model focused on pharmacological treatment
costs and more especially on pharmacy selling prices. In accor-
dance with Finnish health economic guidelines, a 5% discount
rate was applied to both costs and beneﬁts. RESULTS: Begin-
ning treatment of early PD patients with rasagiline delayed time
before levodopa initiation of one year compared with ropinirole
(3.8 vs. 2.8 years). Incremental cost-effectiveness was in favor of
rasagiline with an ICER of €1200 per year gained without lev-
odopa. Initiating treatment with rasagiline has a 95% probabil-
ity of being cost-effective supposing that ropinirole dosage varies
linearily among time. CONCLUSION: This economic model
suggests that initiating treatment with rasagiline for early PD is
more effective in delaying time to levodopa compared with
ropinirole. Further studies are required to link the surrogate end-
point (time without levodopa) to ﬁnal outcomes (QALY, mor-
tality, morbidity).
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OBJECTIVES: There are two preparations of Botulinum toxin
type A—BOTOX and Dysport. Based on BNF prices, the dose
ratio (units of Dysport : BOTOX) for cost equivalence is 4.2 : 1,
however the two products are not interchangeable and there is
no handy conversion factor. This study examined the dose
requirements in a cohort of patients with dystonia who were sta-
bilised ﬁrst on Dysport then on BOTOX. The main objective was
to evaluate the costs of each product in clinical practice.
METHODS: Data was extracted retrospectively from case notes.
Patients were included in the analysis if they had received each
product for at least one year and had demonstrated a response
to both. Those changed back to Dysport at any time during the
2-year period following the switch were excluded. Injections
given in the 1-year period before the switch and between 1 and
2 years after the switch were included in the analysis. The mean
dose of each toxin, the ratio and corresponding costs (from latest
BNF) were calculated. RESULTS: Forty-two patients received
300 administrations. For spasmodic torticollis (36 patients) the
mean doses of BOTOX and Dysport were 89 (range 53 to 120)
and 397 (range 200 to 500) units respectively. The mean ratio
for this indication (Dysport : BOTOX) was found to be 4.48 : 1
(95% conﬁdence interval 4.22 : 1 to 4.73 : 1; range 2.6 : 1 to 
6.3 : 1). For this indication, the mean costs per administration
were found to be ≤115 and ≤122 based on units used and ≤140
and ≤153 based on whole vials for BOTOX and Dysport respec-
tively. Similar ratios were found for other types of dystonia
giving an overall mean dose ratio of 4.56 : 1 (Dysport : BOTOX).
CONCLUSION: This study is consistent with previous work
that has shown that BOTOX is associated with lower costs than
Dysport.
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OBJECTIVE: To explore possible explicative variables of health
and non-health costs related with patient’s life and treatment
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management in adult patients with refractory epilepsy in Spain.
METHODS: A cross-sectional and retrospective study was
designed. Male and female adult patients (above 18 years) with
refractory epilepsy were enrolled in neurology medical settings
between March and September 2005 in Spain. Health care and
non-health care resources were collected and total costs calcu-
lated according with published prices for year 2005. Quality-of-
life, level of anxiety and depression, health state, concomitant
medications and comorbidity history and treatment of epilepsy
were also recorded. A secondary analysis including a forward
stepwise multivariate regression model exploring possible
explicative variables was performed. RESULTS: Seven-hundred-
sixty-two consecutive patients [728 evaluables (95.5%); 50.8%
males, 40.5 (13.5) years, 24.3 (13.4) years of evolution] were
included through the country at epilepsy units, neurology out-
patient clinics and hospital outpatient clinics. A moderate
explicative model was built; adjusted R-square = 0.24 (F = 26.6,
p < 0.0001). Presence of mental retardation and social function
domain of the QOLIE-10 were the variables with most explica-
tive weight of total cost in these patients; standardized estimates
of 0.303 and 0.175, respectively [â coefﬁcient (standard error)
of 6675.0 (826.8) and 53.5 (12.7), p < 0.001 in both cases
respectively]. Health status on a 0–100 mm-VAS (standardized
estimate; 0.142), need for additional non-neurological hospital
assistance (0.118), previous episode of secondarily generalized
seizures (0.102), health care at neurology outpatient clinics
(0.083), and documented etiology of epilepsy (0.096) were all
found to be signiﬁcant explicative variable, all of them p < 0.05.
CONCLUSIONS: This secondary analysis found a broad sources
of drivers of costs in patients with refractory epilepsy in Spain,
with mental retardation and social function domain of QOLIE-
10 (the higher the score the higher the cost) being responsible
for a substantial part of total cost.
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OBJECTIVE: To estimate the cost-effectiveness of pramipexole
versus no treatment in patients with moderate to very severe rest-
less legs syndrome (RLS) in Sweden taking the societal perspec-
tive. METHODS: A cost-utility Markov model was developed
that included ﬁve health states (no, mild, moderate, severe and
very severe RLS) based on the International RLS Study Group
Rating Scale scores. The probability of moving between health
states was derived from the phase III, randomized, double-blind
pramipexole trials in RLS. To comprehensively estimate quality-
adjusted life years (QALYs) several approaches were taken to
map the IRLS to the EQ-5D including Delphi panel, patient
survey and published literature. Treatment patterns were esti-
mated with a physician expert panel. 2005 unit costs were
derived from Swedish government sources. Both one-way and
probabilistic sensitivity analyses were conducted. RESULTS:
Over a one-year time period, treatment with pramipexole
reduced overall costs by SEK 1191 (approximately €128) per
patient and was associated with a gain of 0.035 QALYs relative
to no treatment when using utilities from the Delphi panel.
Pramipexole’s dominance from the societal perspective against
the no treatment alternative was robust to sensitivity analysis.
Sensitivity analyses included variation in health care provider
costs, different utility assumptions, and an extension of the
model to a ﬁve-year time period. CONCLUSIONS: Active treat-
ment of RLS with pramipexole is preferred over no treatment
for patients with moderate to very severe RLS in Sweden.
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OBJECTIVE: To estimate the cost-utility of levodopa-carbidopa
and levodopa-carbidopa-entacapone in the treatment of Parkin-
son disease in the Mexican Institute of Social Security in Mexico.
METHODS: Cost-utility analysis. Use of resources information
was obtained from a retrospective cohort and was validated by
a Mexican expert panel. Costs were estimated from ﬁnancial
information from IMSS, and are reported in US 2006 dollars.
The source of utility information, measured in QALYs, and 
transition probabilities was a meta-analysis and a Mexican
expert panel. Study perspective used: public health services
provider (IMSS); ﬁve years time horizon, 3% real discount rate.
A decision tree with a Bayesian approach and a Markov model
were used. Mean cost-utility, incremental ratios and net health
beneﬁts were estimated. The sensitivity analysis included one-
way, two-way, threshold and probabilistic with Monte Carlo
simulation. RESULTS: Cost per utility unit for levodopa-
carbidopa was $5623 and for levodopa-carbidopa-entacapone,
$5168. Incremental cost-utility ratio using levodopa-carbidopa
as a comparator was $1585. Independently of WTP, levodopa-
carbidopa-entacapone had larger net health beneﬁts than 
levodopa-carbidopa. In the ﬁve years analysis, levodopa-
carbidopa-entacapone showed 12.8% more utility in relation-
ship to levodopa-carbidopa, with 3.5% more costs. The cost per
utility unit with levodopa-carbidopa-entacapone had an accu-
mulated decrease of 18.4% during the period of time analyzed.
The acceptability curves and the component analysis of the
ellipse graph showed that with the actual cost that the IMSS is
investing in the treatment of Parkinson disease, the cost-utility
proportion of levodopa-carbidopa-entacapone would be 80%.
CONCLUSIONS: Levodopa-carbidopa-entacapone had the
lowest cost per unit of success in the treatment of patients with
Parkinson disease compared with levodopa-carbidopa. Cost per
additional utility unit of levodopa-carbidopa-entacapone was
$1585. At the end of the follow-up levodopa-carbidopa-enta-
capone reduced annual health care costs to a greater extent than
levodopa-carbidopa and provided better quality of life per
patient.
PND10
A FUNCTIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN
AGE AND MIGRAINE IN THE UNITED STATES OF AMERICA
Victor TW, Barlas S
Endo Pharmaceuticals, Chadds Ford, PA, USA
OBJECTIVE: The objective of this study was to evaluate the
indirect evidence of menstrual migraine headache by examining
migraine headache prevalence as a function of age. Investigators
have reported that the risk of migraine headache decreases with
age but have not fully described the nature of the decline based
on sex. METHODS: This study was based on data from the
adult sample of the 2003 National Health Interview Survey
(NHIS). The study sample consisted of 17,394 females and
